Loomis, Sayles & Company
MURA

Loomis, Sayles & Company’s Mural Oncology MURA Stock Holding History

Loomis, Sayles & Company’s Portfolio MURA Stock Details MURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,086
Closed -$18K – 876
2023
Q4 		$18K Buy
+3,086
New +$12.4K ﹤0.01% 696

Other funds holding MURA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
AFA
Alta Fundamental Advisers New York $265M AUM 98.61% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Loomis, Sayles & Company's MURA Position: Q1 2024 in Review

Loomis, Sayles & Company sold out of Mural Oncology (MURA) in Q1 2024, closing a stake of 3,086 shares — an estimated $18K sold.

Loomis, Sayles & Company first reported a position in MURA in Q4 2023 and held it in 1 quarter. The position peaked at $18K in Q4 2023. 101 funds tracked by Wall St. Rank hold MURA as of Q1 2024.

  • Loomis, Sayles & Company reported no remaining Mural Oncology position as of Q1 2024 after selling out during the quarter.
  • Loomis, Sayles & Company sold 3,086 Mural Oncology shares in Q1 2024, an estimated $18K.
  • Loomis, Sayles & Company first reported a position in Mural Oncology in Q4 2023 and held it in 1 quarter.
  • Loomis, Sayles & Company's Mural Oncology position peaked at $18K in Q4 2023.
  • 101 funds tracked by Wall St. Rank held Mural Oncology as of Q1 2024.

Based on Loomis, Sayles & Company's 13F filing for Q1 2024, filed 14 May 2024.